Marshall Wace, LLP Viking Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 17,858 shares of VKTX stock, worth $754,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,858
Previous 73,700
75.77%
Holding current value
$754,500
Previous $3.91 Million
71.07%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding VKTX
# of Institutions
473Shares Held
65.6MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$430 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$255 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$197 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$89.4 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$79.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.24B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...